Figure 1.

 Schematic illustration of the potential molecular mechanisms of drug resistance development in epidermal growth factor receptor (EGFR) mutation‐targeted lung cancer therapy in a cancer‐cell‐autonomous and non‐cancer‐cell‐autonomous manner. The robustness of the EGFR signaling network, epigenetic changes, and genetic alterations in cancer cells contribute to drug resistance in a cancer‐cell‐autonomous manner. The interaction between cancer cells and cancer stroma, including stromal cells and ECM, contributes to drug resistance in a non‐cancer‐cell‐autonomous manner.